KRAS and cancer: Interestingly, oncogenic KRAS mutations were shown to increase glucose uptake in cancer cells and lactate production through upregulation of glycolytic genes encoding glucose transporter SLC2A1/GLUT1 and the monocarboxylate transporters SLC16A1/MCT1, SLC16A7/MCT2, and SLC16A3/MCT4 [24, 25, 26].